TipRanks
Advertisement
Advertisement

DE:2VSA Stock Latest News

Verastem announces data from analysis of Phase 2 RAMP 201 trial
The FlyVerastem announces data from analysis of Phase 2 RAMP 201 trial
21h ago
VSTM
Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal
PremiumThe Fly
Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal
5d ago
VSTM
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
PremiumTipRanks Newswire
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
8d ago
AZN
NVS
Verastem initiated with an Outperform at Wolfe Research
PremiumThe Fly
Verastem initiated with an Outperform at Wolfe Research
16d ago
VSTM
Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target
PremiumRatings
Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target
22d ago
VSTM
Verastem to unveil new clinical data on VS-7375
PremiumThe FlyVerastem to unveil new clinical data on VS-7375
25d ago
VSTM
Verastem price target lowered to $13 from $14 at Mizuho
Premium
The Fly
Verastem price target lowered to $13 from $14 at Mizuho
2M ago
VSTM
Verastem price target lowered to $13 from $14 at Mizuho
Premium
The Fly
Verastem price target lowered to $13 from $14 at Mizuho
2M ago
VSTM
Verastem Earnings Call Highlights Cash, Pipeline Momentum
PremiumCompany Announcements
Verastem Earnings Call Highlights Cash, Pipeline Momentum
2M ago
VSTM
Verastem Restructures Oberland Financing to Support Commercialization
PremiumCompany Announcements
Verastem Restructures Oberland Financing to Support Commercialization
2M ago
8K
VSTM
Verastem price target lowered to $12 from $14 at Guggenheim
PremiumThe Fly
Verastem price target lowered to $12 from $14 at Guggenheim
2M ago
VSTM
Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained
PremiumRatings
Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained
2M ago
VSTM
Verastem reports Q2 adjusted EPS (31c), consensus (44c)
PremiumThe FlyVerastem reports Q2 adjusted EPS (31c), consensus (44c)
2M ago
VSTM
Is VSTM a Buy, Before Earnings?
Premium
Pre-Earnings
Is VSTM a Buy, Before Earnings?
2M ago
VSTM
Verastem doses first patients in Target-D 203 Phase 2 trial
Premium
The Fly
Verastem doses first patients in Target-D 203 Phase 2 trial
2M ago
VSTM
Verastem doses first patient in TARGET-D 202 Phase 2 trial
PremiumThe Fly
Verastem doses first patient in TARGET-D 202 Phase 2 trial
2M ago
VSTM
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens healthcare analysts hold an analyst/industry conference call
3M ago
CTMX
EXEL
Verastem price target lowered to $14 from $15 at RBC Capital
PremiumThe Fly
Verastem price target lowered to $14 from $15 at RBC Capital
3M ago
VSTM
Verastem Advances VS-7375 with Promising Early Trial Data
PremiumCompany Announcements
Verastem Advances VS-7375 with Promising Early Trial Data
3M ago
8K
VSTM
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
PremiumThe FlyVerastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
3M ago
VSTM
Verastem price target lowered to $8 from $15 at Jefferies
Premium
The Fly
Verastem price target lowered to $8 from $15 at Jefferies
3M ago
VSTM
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
Premium
Company Announcements
Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial
4M ago
8K
VSTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >